Explore

TrendlineTrendline
Novo Nordisk Engages DJ Khaled for Wegovy Campaign Amidst Oral Weight Loss Drug Competition

Novo Nordisk Engages DJ Khaled for Wegovy Campaign Amidst Oral Weight Loss Drug Competition

Novo Nordisk Engages DJ Khaled for Wegovy Campaign Amidst Oral Weight Loss Drug Competition
ReutersReuters
CVS says GLP-1s save money when priced below $350 per month

CVS says GLP-1s save money when priced below $350 per month

By Amina Niasse NEW YORK, Nov 14 (Reuters) - CVS Health said employers and other health plan sponsors could break even on GLP-1 drugs if they are priced below $350 per month as reduced use of medical services, such as hospitalizations and emergency room visits, lower spending enough to offset drug
Rapid ReadRapid Read
GLP-1 Medications Show Promise in Influencing Epigenetic Aging Markers and Extending Lifespan in Mice

GLP-1 Medications Show Promise in Influencing Epigenetic Aging Markers and Extending Lifespan in Mice

Recent research presented at the 2026 Aging Research and Drug Discovery Meeting indicates that GLP-1 medications, such as semaglutide and tirzepatide, are positively influencing epigenetic aging clocks. Novo Nordisk reported that semaglutide improved biological aging measures across multiple organ systems, including the heart and kidneys. Similarly, Eli Lilly presented findings that tirzepatide, found in prescriptions like Mounjaro and Zepbound, affected several epigenetic aging clocks, including organ-specific markers for the heart, kidney, liver, and immune system. A study published in Nature also found that semaglutide extended the lifespan of older female mice by approximately 12 percent, alongside improvements in physical and cognitive function. These independent observations suggest that GLP-1-based therapies may impact biological aging through various molecular pathways, extending these molecular observations to actual lifespan and demonstrating improvements in several hallmarks of aging.
TrendlineTrendline
Eli Lilly's Orforglipron Approved in China, Gaining Edge in Oral GLP-1 Obesity Market

Eli Lilly's Orforglipron Approved in China, Gaining Edge in Oral GLP-1 Obesity Market

Eli Lilly's Orforglipron Approved in China, Gaining Edge in Oral GLP-1 Obesity Market
Rapid ReadRapid Read
Cleveland Clinic Study Reveals Bariatric Surgery as Most Effective for Weight Loss Post-GLP-1 Drug Discontinuation

Cleveland Clinic Study Reveals Bariatric Surgery as Most Effective for Weight Loss Post-GLP-1 Drug Discontinuation

New research from Cleveland Clinic, published in eClinicalMedicine, indicates that patients who discontinue injectable GLP-1 drugs like semaglutide or tirzepatide achieve the greatest long-term weight loss if they subsequently undergo bariatric surgery. The study analyzed electronic health records of 20,486 Cleveland Clinic patients who used these medications for at least three months between 2021 and 2023. Patients who switched between semaglutide and tirzepatide, remained on their initial medication, or transitioned to other obesity treatments also experienced significant weight loss over a two-year follow-up period. In contrast, those who stopped treatment without further intervention showed the least weight loss and minimal improvements in blood sugar control and blood pressure. Lead author Hamlet Gasoyan, Ph.D., a researcher with Cleveland Clinic’s Center for Value-Based Care Research, is scheduled to present these findings at ObesityWeek 2026.
Rapid ReadRapid Read
Ozempic Manufacturer Novo Nordisk Faces Lawsuits Over Alleged Vision Loss Side Effect

Ozempic Manufacturer Novo Nordisk Faces Lawsuits Over Alleged Vision Loss Side Effect

Novo Nordisk, the manufacturer of the GLP-1 medication Ozempic, is facing over 200 lawsuits in the U.S. from individuals claiming the drug caused partial blindness. One such plaintiff, Jay Vandegriff, was prescribed Ozempic in 2023 for type 2 diabetes and experienced a sudden loss of vision on Christmas Day 2024, leading to a diagnosis of non-arteritic anterior ischemic optic neuropathy (NAION). NAION is an optic nerve stroke caused by reduced blood flow, resulting in sudden and often irreversible vision loss. Vandegriff's legal team, Weitz & Luxenberg, states that the risk of NAION was not listed on the U.S. label for Ozempic when he was taking it. The U.S. Food and Drug Administration (FDA) recently announced that GLP-1 medicines must now carry a warning about a potential increased risk of NAION, months after the UK's Medicines and Healthcare products Regulatory Agency (MHRA) issued a similar safety update.
Rapid ReadRapid Read
Yale Meta-Analysis Reveals Medications and Lifestyle Changes Reduce Biological Age, Not Most Supplements

Yale Meta-Analysis Reveals Medications and Lifestyle Changes Reduce Biological Age, Not Most Supplements

A new meta-analysis conducted by Yale researchers indicates that certain prescription medications and combined lifestyle interventions can effectively reduce biological age, as measured by DNA methylation blood tests. The study, which synthesized data from 51 clinical studies, found that drugs like metformin and semaglutide, along with lifestyle changes such as diet and exercise, show robust effects in slowing biological aging. Conversely, the analysis revealed that most popular over-the-counter supplements generally do not have a significant impact on biological age. This research utilized advanced DNA methylation-based epigenetic clocks, including GrimAge, PhenoAge, and DunedinPACE, to assess changes in biological age, providing a systematic comparison of various anti-aging strategies. The findings align with existing scientific literature that supports the efficacy of pharmaceutical and comprehensive lifestyle approaches in modifying aging biomarkers.
Rapid ReadRapid Read
FDA Mandates New Vision Loss Warnings for Ozempic, Wegovy, and Zepbound

FDA Mandates New Vision Loss Warnings for Ozempic, Wegovy, and Zepbound

The U.S. Food and Drug Administration (FDA) has issued a directive requiring manufacturers of GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, to update their prescribing labels. The new labels must include a warning about the potential risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can lead to sudden, painless, and sometimes permanent vision loss. This decision follows a comprehensive safety review by the FDA, which analyzed randomized clinical trials, animal studies, post-marketing patient reports, and real-world observational data. While the overall incidence of NAION remains uncommon, the FDA's analysis of clinical trials showed 6.4 cases per 100,000 person-years in GLP-1 users compared to 3.8 cases in control groups. Drugmakers like Eli Lilly and Novo Nordisk have acknowledged the FDA's update, with Novo Nordisk stating that current data does not definitively prove a causal link and maintaining confidence in their medicines' benefit-ris...
ReutersReuters
Eli Lilly becomes first drugmaker to have a GLP-1 weight loss pill approved in China

Eli Lilly becomes first drugmaker to have a GLP-1 weight loss pill approved in China

By Andrew Silver SHANGHAI, Nov 12 (Reuters) - Eli Lilly on Thursday became the first company to have a GLP-1 weight-loss pill approved in China, gaining a leg up on Danish rival Novo Nordisk in the world's second-largest pharmaceutical market.
TrendlineTrendline
Highmark Pharmacy Innovates Value-Based Employee Benefits to Manage Healthcare Costs

Highmark Pharmacy Innovates Value-Based Employee Benefits to Manage Healthcare Costs

Highmark Pharmacy Innovates Value-Based Employee Benefits to Manage Healthcare Costs
Rapid ReadRapid Read
Cleveland Clinic Researchers Advance Dual-Target siRNA Therapy for Mixed Hyperlipidemia

Cleveland Clinic Researchers Advance Dual-Target siRNA Therapy for Mixed Hyperlipidemia

Cleveland Clinic researchers have presented first-in-human findings on a novel dual-function small interfering RNA (siRNA) therapeutic, ARO-DIMER-PA, designed to simultaneously lower both LDL cholesterol (LDL-C) and triglycerides. This development addresses mixed hyperlipidemia, a common lipid disorder that typically requires separate treatments for its components. The phase 1/2a trial, presented at the American Heart Association’s 2026 Scientific Sessions, demonstrated that a single dose of ARO-DIMER-PA sustained suppression of both PCSK9 and APOC3 proteins, leading to substantial reductions in LDL-C (26% to 65%) and triglycerides (56% to 78%). The drug was generally well tolerated, with injection-site erythema being the most common adverse event. This bifunctional therapy represents a significant step forward, as existing siRNA drugs typically target only one of these proteins.
Rapid ReadRapid Read
Christopher D. Miller Co-Authors Study on Argatroban Use in Heparin-Induced Thrombocytopenia

Christopher D. Miller Co-Authors Study on Argatroban Use in Heparin-Induced Thrombocytopenia

Christopher D. Miller is among the authors of a new study published in 'The Annals of Pharmacotherapy' on November 11, 2026. The research, titled 'Comparing Length of Argatroban Use Among Patients Managed With Warfarin Versus Apixaban or Rivaroxaban for the Treatment of Suspected Heparin-Induced Thrombocytopenia,' investigates the duration of argatroban administration when patients with suspected or acute heparin-induced thrombocytopenia (HIT) are transitioned to different oral anticoagulants. The single-center retrospective chart review included 17 patients in the apixaban and rivaroxaban group and 27 patients in the warfarin group. The study found that patients transitioned to apixaban or rivaroxaban had a significantly shorter duration of argatroban infusion (3.8 days) compared to the warfarin group (11.2 days), with a P-value of less than 0.001.